TRC-160334 is under clinical development by Torrent Pharmaceuticals and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect TRC-160334’s likelihood of approval (LoA) and phase transition for Ulcerative Colitis took place on 07 Jun 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their TRC-160334 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

TRC-160334 overview

TRC-160334 is under development for the treatment of ulcerative colitis. The drug candidate is administered through intravenous route. It is a new chemical entity which acts by targeting hypoxia-inducible factor hydroxylase. It was under development for the treatment of inflammatory bowel disease including crohn's disease and acute kidney injury (AKI)

Torrent Pharmaceuticals overview

Torrent Pharmaceuticals (Torrent) manufactures and markets branded and unbranded generic pharmaceuticals. It provides products in cardiovascular, central nervous system, gastro-intestinal, diabetology, anti-infective, urology and pain management therapeutic areas. The company also has presence in nephrology, cancer, gynecology and pediatric segments. It offers contract manufacturing services at its manufacturing facilities for formulation and API. Torrent has a fully equipped research center that is approved by the US FDA and various other regulatory authorities and manufacturing facilities at Indrad, Baddi, Sikkim, Dahej, Vizag and Pithampur. The company has presence through its operations in the US, the UK, Germany, Russia, Brazil, Mexico, Philippines and other major markets. Torrent is headquartered in Ahmedabad, Gujarat, India.

Quick View TRC-160334 LOA Data

Report Segments
  • Innovator
Drug Name
  • TRC-160334
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Gastrointestinal
  • Genito Urinary System And Sex Hormones
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.